LB-1

ProPhase Labs Teams up with Certis Oncology to Accelerate Development of Novel Linebacker Compound

Retrieved on: 
Thursday, August 3, 2023

“We have tested the novel Linebacker compound against hundreds of cancers and thousands of pathways, but will continue testing to the extent we believe useful data may be obtainable,” says Ted Karkus, CEO of ProPhase Labs.

Key Points: 
  • “We have tested the novel Linebacker compound against hundreds of cancers and thousands of pathways, but will continue testing to the extent we believe useful data may be obtainable,” says Ted Karkus, CEO of ProPhase Labs.
  • “Our team is very pleased to be working with ProPhase on the Linebacker initiative.
  • “Savvy investors expect this now, and with good reason, and ProPhase will continue to lead the pack and push the boundaries forward.
  • We are looking forward to initiating Phase I human studies next year at a modest budget of approximately $3+ million dollars for all planned studies.

ProPhase Labs’ Cancer Therapeutic, Linebacker-1, pre-clinical studies with Dana Farber/Harvard Cancer Institute demonstrate impressive utility and move into next phase of testing

Retrieved on: 
Thursday, June 1, 2023

Garden City, NY, June 01, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a next generation biotech, genomics and diagnostics company, today provided an update regarding its progress and development strategy for Linebacker-1 (LB-1), a small molecule, multi-kinase inhibitor that is being developed by the Company’s wholly owned subsidiary, ProPhase BioPharma, Inc. (“PBIO”), as a potential unique therapy option for several poor prognosis cancers.

Key Points: 
  • Harvard scientists at the Dana Farber Cancer Institute, in two separate lung and colon cancer clonogenic models, have successfully demonstrated Linebacker’s ability to inhibit cancer cell growth, an exciting development for the polyphenol compound.
  • Also observed were synergies between Linebacker and low doses of frontline chemotherapeutic agents such as Doxorubicin in the colon cancer model.
  • With proof-of-principle demonstrated, the ProPhase team is moving forward with in-depth cancer modeling to precisely hone-in on optimal clinical pathways for development.
  • We are looking forward to Phase I human studies next year at a modest budget of approximately $3+ million dollars for all planned studies.

ProPhase Labs hires Dr. Matthew Halpert to Drive Company’s Key Therapeutic and Diagnostic Oncology Programs

Retrieved on: 
Monday, May 8, 2023

Dr. Halpert will also assist the ProPhase team on other new and exciting programs which will be announced at a later date as they advance in pre-clinical testing.

Key Points: 
  • Dr. Halpert will also assist the ProPhase team on other new and exciting programs which will be announced at a later date as they advance in pre-clinical testing.
  • “Having started several oncology focused companies, Dr. Halpert is perfectly qualified to help ProPhase develop Linebacker-1 as both a mono-therapy and co-therapy in several difficult to treat cancers,” commented Ted Karkus, CEO of ProPhase Labs.” “Dr.
  • Halpert will be a key participant in trial design, regulatory preparation and the potential commercialization of numerous therapeutic products at the Company.
  • Dr Halpert has both the expertise and experience to assist and guide PBIO assets through all regulatory steps toward commercialization.”
    “Dr.

ProPhase Labs’ Linebacker-1 Cancer Therapeutic shows promising mechanisms of action as both a mono-therapy and co-therapy in preclinical studies attacking a range of hard-to-treat cancers, including lung and gastric cancers

Retrieved on: 
Wednesday, May 3, 2023

ProPhase was excited to learn that numerous critically important kinase targets were inhibited more than 99%.

Key Points: 
  • ProPhase was excited to learn that numerous critically important kinase targets were inhibited more than 99%.
  • We believe the unique interplay of Linebacker with multiple cancer-dependent pathways will be a true differentiator within current treatment paradigms.
  • In line with these impressive results, Linebacker-1 has demonstrated strong preclinical potential in a number of difficult diseases, including tough-to-treat lung and gastric cancers.
  • We look forward to providing updates in the coming weeks on additional Linebacker pre-clinical studies that are being conducted in parallel.

ProPhase Labs Announces Record Financial Results for the year ended December 31, 2022

Retrieved on: 
Tuesday, March 28, 2023

Garden City, NY, March 28, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today reported its financial and operational results for the year ended December 31, 2022.

Key Points: 
  • Financial highlights for the full year ended December 31, 2022, include the following:
    Net revenue of $122.6 million for the year ended December 31, 2022, as compared to $79.0 million for the year ended December 31, 2021, an increase of approximately 55%.
  • Adjusted EBITDA of $38.6 million for the year ended December 31, 2022, as compared to adjusted EBITDA of $18.1 million for the year ended December 31, 2021.
  • For the year ended December 31, 2022, our overall gross margin was 57.6% as compared to 53.1% for the year ended December 31, 2021.
  • Research and development costs for the year ended December 31, 2022 were $0.7 million as compared to $0.5 million for the year ended December 31, 2021.

ProPhase Labs Announces New $6 Million Stock Repurchase Program

Retrieved on: 
Wednesday, March 15, 2023

Garden City, NY, March 15, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced that its Board of Directors has authorized a stock repurchase program of up to $6 million in ProPhase Labs’ common stock.

Key Points: 
  • Garden City, NY, March 15, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced that its Board of Directors has authorized a stock repurchase program of up to $6 million in ProPhase Labs’ common stock.
  • During the past six months, between purchasing stock in the open stock market and retiring shares from stock option exercises, the Company retired a total of 1.2 million shares of common stock.
  • The Board of Directors of the Company will re-evaluate the program from time to time and may authorize adjustments to its terms.
  • The Company expects to utilize its existing funds to fund repurchases under the repurchase program.

ProPhase Labs Provides Update on Linebacker-1 Cancer Co-Therapy Program and Outlines Development Strategy

Retrieved on: 
Monday, February 6, 2023

“We are excited to provide this update on our progress with the Linebacker-1 cancer co-therapy program, a platform which we believe has multi-billion-dollar potential in oncology as well as significant potential in other areas,” commented Ted Karkus, ProPhase Lab’s Chief Executive Officer.

Key Points: 
  • “We are excited to provide this update on our progress with the Linebacker-1 cancer co-therapy program, a platform which we believe has multi-billion-dollar potential in oncology as well as significant potential in other areas,” commented Ted Karkus, ProPhase Lab’s Chief Executive Officer.
  • The ongoing studies are focused on identifying the most effective combination of cancer cell lines and agents with LB-1.
  • Initial focus areas include hepatic, colon and breast cancer, and initial therapy agents include Topotecan and Doxorubicin.
  • The Company estimates that the total cost for development prior to exploring a strategic partner will be $3 - $5 million.

ProPhase Labs to Present at the Planet MicroCap Showcase: VIRTUAL 2022 on Wednesday, December 7, 2022

Retrieved on: 
Wednesday, November 30, 2022

GARDEN CITY, NY, Nov. 30, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced that it will be presenting at the Planet MicroCap Showcase: VIRTUAL 2022 on Wednesday, December 7, 2022 at 2:30 pm EST.

Key Points: 
  • GARDEN CITY, NY, Nov. 30, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced that it will be presenting at the Planet MicroCap Showcase: VIRTUAL 2022 on Wednesday, December 7, 2022 at 2:30 pm EST.
  • The Company provides traditional CLIA molecular laboratory services, including COVID-19 testing.
  • ProPhase Diagnostics also offers best-in-class rapid antigen and antibody/immunity tests to broaden its COVID-19 testing beyond RT-PCR testing.
  • ProPhase BioPharma, Inc. (PBIO), a wholly owned subsidiary of ProPhase, was formed for the licensing, development and commercialization of novel drugs and compounds.

ProPhase Labs Announces Collaboration with Dana-Farber Cancer Institute

Retrieved on: 
Tuesday, November 8, 2022

This collaboration provides for year 1 and year 2 research plans and will examine the tumoricidal effects of the flavonoid/polyphenol.

Key Points: 
  • This collaboration provides for year 1 and year 2 research plans and will examine the tumoricidal effects of the flavonoid/polyphenol.
  • ProPhase Labs is eager to explore new avenues for scientific discovery with these talented scientists as we pursue novel pathways for cancer treatment.
  • ProPhase BioPharma, Inc. (PBIO), a wholly owned subsidiary of ProPhase, was formed for the licensing, development and commercialization of novel drugs and compounds.
  • The company is collaborating with the Dana Farber Cancer Institute to develop LB-1 as a cancer co-therapy.

ProPhase Labs to Present at Investor Summit Group’s Q4 Conference

Retrieved on: 
Tuesday, November 8, 2022

ET

Key Points: 
  • ET
    Sheraton New York Times Square Hotel, 811 7th Avenue, W 53rd St, New York,
    The conference is completely complimentary to qualified investors.
  • Please register at Complimentary I n vestor Registr a tion
    ProPhase Labs, Inc. (Nasdaq: PRPH) (ProPhase) is a growth oriented and diversified diagnostics, genomics and biotech company.
  • ProPhase Diagnostics also offers rapid antigen and antibody/immunity tests to broaden its COVID-19 testing beyond RT-PCR testing.
  • ProPhase Labs actively pursues strategic investments and acquisition opportunities for other companies, technologies, and products.